Ann: ResAppDx-EU to be deployed on the Coviu Telehealth Platform, page-85

Further dodgy estimates of Resapp potential revenue from Coviu -

• As at December 2019 there were 40,844 GPs in Australia (Medical Board of Australia)
• On average GPs have 100 patient encounters per week for 50 weeks of the year (General Practitioners of Australia)
• Assume 30% of consultations are respiratory related (anecdotal range is 30% to 50% from other HC posters) and all of these utilise Resapp
• Assume GPs comprise 20% of 7000 Coviu members
• Price per ResApp test of $5

So 1,400 Coviu doctors (20% of 7,000) perform 1,500 Resapp tests pa (30% x 100 x 50) at $5 = $10.5M pa

The government's response to COVID-19 introduces new temporary Medicare Benefits Schedule items to allow doctors, nursers and mental health professionals to deliver services via Telehealth allowing people to access health services while in self isolation or quarantine to limit spread of the virus. This will be reviewed in six months. Therefore many more GPs will register with Telehealth platforms including Coviu to provide these services.

Initially, Coviu will be the only Telehealth provider with Resapp incorporated into their platform. Coviu should be promoting this to GPs as a significant point of difference to other Telehealth platforms. If Coviu captured 10% of Australia's GPs, revenue would more than double.

Importantly, the Federal Government will need to be lobbied to continue the Telehealth MBS items beyond the 6 month trial. If the trial is discontinued, there could be significant revenue reductions as Telehealth consultations (apart from remote areas and nursing homes) would no longer be bulk billed. Resapp/Coviu and industry peak bodies should be planning significant advocacy for the trial to become a permanent arrangement.

Happy to be corrected on any of the above. DYOR!